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ABSTRACT
Introduction: We have analyzed the short- and long-
term results of various surgical therapies for achalasia,
especially changes in postoperative esophageal function.
Patients and Methods: Between January 1, 2008 and
December 31, 2017, 54 patients with esophageal achala-
sia were treated in our institution. Patients scheduled for
surgery underwent a comprehensive gastroenterological
assessment pre- and post-surgery. Forty-eight of the elec-
tive cases involved a laparoscopic cardiomyotomy with
Dor’s semifundoplication, while two cases entailed
an esophageal resection with an intrathoracic gastric
replacement for end-stage achalasia. Torek’s operation
was performed on two patients for iatrogenic esophageal
perforation, and two others underwent primary suture
repair with Heller–Dor surgery as an emergency proce-
dure. The results of the different surgical treatments, as
well as changes in the patients’ pre- and post-operative
complaints were evaluated.
Results: No intra-operative complications were observed,
and no mortalities resulted. During the 12 to 24-month
follow-up period, recurrent dysphagia was observed
mostly in the spastic group (TIII: 33%; diffuse esophageal
spasm: 60%), while its occurrence in the TI type did not
change significantly (14.5%–20.8%). As a result of the fol-
low-up of more than two years, good symptom control
was achieved in 93.7% of the patients, with only four
patients (8.3%) developing postoperative reflux.
Conclusions: The laparoscopic Heller–Dor procedure
provides satisfactory long-term results with low morbid-
ity. In emergency and advanced cases, traditional surgical
procedures are still the recommended therapy.
Key Words: Esophageal achalasia, Minimally invasive
surgery, Myotomy, Megaesophagus, Iatrogenic esopha-
geal injury.
INTRODUCTION
First described by Sir Thomas Willis in 1674, achalasia is a
chronic motility disorder of the esophagus characterized
by a lack of peristalsis and the inability of the lower
esophageal sphincter (LES) to relax.1,2 Despite being rare,
it is the most common primary motor disorder of the
esophagus with an incidence of 1/100,000 and a preva-
lence of 10/100,000;3 no gender predominance can be
observed. It may be developed at any age, but it occurs
most commonly in the third to fifth decade of life. The eti-
ology of achalasia is still unclear, but, ultimately, it is a
selective disorder of the inhibitory neurons in the myen-
teric (or Auerbach’s) plexus of the distal esophagus and
the LES. In most cases, clinical presentation is dominated
by progressive dysphagia, regurgitation, and chest/epi-
gastric pain, with heartburn and coughing at night also
common. In gastroenterological diagnostics, functional
assessments play a primary role. Currently, the new high-
resolution manometry (HRM), which is becoming the
gold standard, facilitates an accurate diagnosis, which
may consist of the following abnormal esophageal proc-
esses: aperistalsis, abnormal LES relaxation, and a dilated
esophagus. HRM makes it possible to distinguish three
types of esophageal motility disorder, which can be classi-
fied based on the Chicago Classification.4 Type I (which
corresponds to the previous classic type) refers to aperis-
talsis of the esophageal body and a relaxation disorder of
the LES. In type II (compression), the morphology of
waves in the esophageal body is the same as that seen in
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type I, but the amplitudes exceed 30mmHg. In type III
(spastic), tall (> 200mmHg), wide contractions can be
seen in the distal esophagus.
The treatment for achalasia is palliative only, and all
therapeutic efforts are aimed at facilitating adequate
passage through the cardia and, at the same time, pre-
venting late structural and functional esophageal com-
plications. Non-surgical therapies for achalasia include:
local administration of smooth muscle relaxants and
botulinum toxin, which has a lower efficacy; endo-
scopic balloon dilation (EBD), which is popular for its
efficacy; and the new, highly promising peroral endo-
scopic myotomy (POEM) used primarily in East Asia
and at a few Western centers.
The safest and most effective treatment for achalasia is
still surgery, which involves cutting the muscle fibers
of the abnormally functioning lower esophageal
sphincter (a Heller cardiomyotomy). The minimally
invasive (laparoscopic and thoracoscopic) types of
Heller myotomy were introduced into clinical practice
in the early 1990s.5,6 Results from the first thoraco-
scopic esophagotomy performed for achalasia in
Hungary were published by staff at the Department of
Surgery, University of Szeged (Hungary); the proce-
dure was well tolerated by the patients, and their swal-
lowing functions improved.7
To reduce the risk of gastroesophageal reflux disease
(GERD) following a cardiomyotomy, which had previ-
ously been used alone, the procedure was later com-
pleted with partial fundoplication (anterior – Dor, or
posterior – Toupet). This modified laparoscopic Heller
cardiomyotomy completed with semifundoplication has
proved to be the most effective procedure, with minimal
morbidity, both in the short and long term.8
Management of advanced and emergency cases forms a
separate group in the treatment of achalasia. Without
proper therapy, in the case of inadequate treatment or as
a result of the natural progression of the disease, esopha-
geal dilation, deformity, and at the same time, loss of
function occur, leading to an end-stage disease in about
5% of cases.9 In these advanced cases, esophageal resec-
tion ensures the best results. The most serious complica-
tion in the endoscopic treatment of achalasia is
esophageal perforation, which also requires surgical ther-
apy. The type of surgical intervention (sutures with a my-
otomy and resection) and the other endoscopic
therapeutic modalities are determined by the stage of the
underlying disease, the general condition of the patient
and the time from perforation to treatment.
In this paper, we analyze our experience with the com-
plex surgical treatment of esophageal achalasia, empha-
sizing the choice of a proper treatment strategy and type
of surgery, as well as the long-term changes in quality of
life.
PATIENTS AND METHODS
Between January 1, 2008 and December 31, 2017, 54
patients (24 males and 30 females aged 17 to 79 years)
with symptomatic esophageal achalasia were treated at
the Department of Surgery, University of Szeged
(Hungary). The most common complaints among the
patients scheduled for surgery included dysphagia, solid
food becoming stuck, epigastric pain, and less frequently,
weight loss. The mean duration of the symptoms was
57.3months (3–192). After a detailed history was taken,
patients underwent a comprehensive gastroenterological
assessment (a swallowing X-ray examination, upper gas-
trointestinal endoscopy, esophageal pH-metry, and ma-
nometry). Based on the Chicago Classification, the types
of achalasia in the laparoscopic group were as follows: TI,
TII, and TIII achalasia was found in 30, 3, and 9 cases,
respectively; diffuse esophageal spasm (DES) was con-
firmed in 5 cases; and Jackhammer esophagus was
observed in 1 patient. Clinical presentation of megaeso-
phagus was diagnosed in 4 cases. Among the patients in
the laparoscopic group, 18.7% (9/48) and all the patients
in the acute and the reconstruction groups (4/4, 100%; 2/
2, 100%) were treated with pre-operative endoscopic bal-
loon dilation.
Surgical Treatment Elective Laparoscopic Heller–
Dor Surgery
Forty-eight patients underwent a laparoscopic Heller car-
diomyotomy and Dor’s anterior partial fundoplication.
With the supine patient in a reverse Trendelenburg posi-
tion, ports were inserted into the abdominal cavity: three
ports, with 15-cm intervals, along the left costal margin;
one port in the epigastric region, to the right of the mid-
line; and one port (camera port) of 10 to 12mm in diame-
ter directly above the umbilicus. After creating a
pneumoperitoneum, the abdominal, lower mediastinal
segment of the esophagus was mobilized, maintaining an
intraabdominal pressure of 15mmHg. Esophageal mucosa
integrity was checked with intraoperative endoscopy in
each case. A Heller esophago-cardiomyotomy was per-
formed over a length of 8 cm on the anterior wall of the
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esophagus, and over at least 2 cm on the gastric fundus,
completed with Dor’s partial anterior fundoplication.
Elective Esophageal Resection
Megaesophagus patients underwent surgery after bowel
preparation, and ulcer, thrombosis, and antibiotic prophy-
laxis. Gastric replacement involved an upper midline lapa-
rotomy, widening the esophageal hiatus and then
mobilizing the esophagus through the hiatus. After mobiliz-
ing the stomach and ligating the left gastric artery, a gastric
conduit was created as per Akiyama using linear staplers
along the lesser curvature, and then a jejunal feeding cathe-
ter was implanted. After drainage, the abdominal section
was closed, the patient was turned to a left lateral decubitus
position, and the esophagus was subtotally resected through
a right anterolateral thoracotomy with selective intubation.
The gastric conduit was pulled from the abdominal cavity
through the enlarged hiatus into the thorax, where an anas-
tomosis was performed between the esophagus and the
stomach with a circular stapler.
In a patient who had previously undergone a Heller–
Toupet operation and then developed recurrent symp-
toms and megaesophagus, the previous fundoplication
was eliminated, the lower third of the esophagus and the
cardia were resected, and they were replaced with an iso-
peristaltic jejunal segment positioned under the azygos
vein (the Merendino procedure).
Emergency Surgical Interventions
Four patients underwent emergency surgery for an iatro-
genic esophageal perforation due to EBD. In two cases, pri-
mary suture repair and Heller–Dor surgery were performed
with traditional open surgery, using intraoperative endo-
scopic control, in non-septic patients with early-stage acha-
lasia (within 8 hours). In another two emergency cases,
iatrogenic perforation of megaesophagus was confirmed.
More than 24hours had passed between the injury and the
surgical treatment, and the patients were in a severe septic
condition at the time of surgery. In one of the patients, the
perforation was caused by a diagnostic esophagoscopy per-
formed at another institution, while the other patient devel-
oped a rupture after EBD, which was followed by two
unsuccessful attempts at endoscopic clipping. Both patients
underwent an esophagectomy as per Torek, a gastrotube
was used for decompression purposes, and a jejunal feeding
catheter was implanted.
Reconstructive Surgery
Ninety-nine and 122 days after Torek’s esophageal resec-
tion, successful substernal reconstruction was performed
using the right colon and the stomach, respectively.
Postoperative Care
For the postoperative period, patients in the laparoscopic
group were transferred to the surgery unit after recovery
from anesthesia. Parenteral fluid therapy was adminis-
tered during the postoperative period. Enteral feeding
was gradually introduced after the swallowing X-ray ex-
amination was conducted on postoperative day 2 if noth-
ing abnormal was detected. Patients in the elective
esophageal resection group spent three days on average
(two to four days) in our department’s intensive care unit
for close monitoring. Once they were stable, they were
transferred to our ward, where they received total paren-
teral feeding. A swallowing X-ray examination with a
water-soluble contrast agent routinely followed on post-
operative day 7. If the leak test was negative, the protocol
for the gradual introduction of enteral feeding was the
same as in the laparoscopic group.
Follow-up
Patients treated with a laparoscopic myotomy were given
gastroenterological check-ups (a swallowing X-ray,
esophageal manometry, pH-metry, and esophago-gastros-
copy) an average of three months after the surgery – these
assessments were carried out in 37 patients. Regular fol-
low-up occurred with a total of 27 patients, while 10
patients did not return for the periodic follow-up visits af-
ter the initial period (months 2 and 6 post-surgery),
although nine of them were complaint-free.
ETHICS
The study was registered with Regional Human Biomedical
Research Ethics Committee, with the identifier 4827.
RESULTS
Postoperative Results
The average duration of the laparoscopic procedures was
72 (62–90) minutes with minimal blood loss (50 to
100mL). No intraoperative complications were observed,
and conversion was required in one case (1/48, 2%) for
adhesions. The swallowing test conducted with a water-
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soluble contrast agent (Gastrografin®) on postoperative
day 4 (on average) revealed a leak from the site of the
sutures in one case (1/48, 2%), which was treated with
emergency re-operation and suture placement. The aver-
age length of stay was 7.3 (5–28) days in the elective, lapa-
roscopic group.
There was one case of hydrothorax formation requiring a
puncture and one case of atrial fibrillation in the emergency
surgery group. There were no mortalities. Patients with pri-
mary suture repair were discharged after 16.5 (13–20) days,
following a swallowing X-ray with normal results, while
those who had undergone Torek’s operation were dis-
charged after 15.5 (14–17) days. Later, the reconstructive
surgeries performed with a colon or gastric pull-up after
Torek’s operation were accompanied by neither intraopera-
tive nor postoperative complications, and patients were dis-
charged on day 14.5 after a swallowing X-ray with normal
results and gradually introduced oral feeding (Table 1).
Long-term follow-up
At the 1 to 6-month follow-up visit, all the patients, except
for one, reported unrestricted swallowing, which was also
confirmed by functional assessments. Those returning for
later gastroenterological check-ups were evaluated based on
follow-up intervals and their swallowing function (Table 2).
At the 6 to 12-month follow-up visit, non-severe recurrent
dysphagia was reported in eight patients. In two cases, di-
etary changes and medical treatment resulted in notable
improvement, while persistent complaints were recorded
despite therapy in two others. EBD was required in an
additional four cases (8.3%), with one of these patients
requiring esophageal resection for recurrent complaints
despite the EBD, considering the patient’s young age and
the significantly dilated esophagus. At the 12 to 24-month
visit, the number of patients being followed up for dys-
phagia (8) had not changed, but there were three new
cases. Medical therapy was successful in one, and a suc-
cessful EBD was performed in another; however, one
patient had persistent complaints. During the follow-up
visits after 24months, a total of seven patients were fol-
lowed up for dysphagia, one of them being a new patient,
who became complaint-free after conservative therapy.
Those with complaints despite surgery mostly suffered
from spastic motility disorders (TIII and DES).
Postoperative reflux did not occur during the 6–12-month
follow-up period, while it developed in three patients in
total (3/48, 60.2%) during the 12–24-month and >24-month
follow-up; however, it was controlled well medically.
Our study also revealed that at the 12 to 24-month follow-
up visits, symptomatic, and symptom-free patients had
undergone surgery at approximately the same age
(53.5 years vs. 48.1 years), and the duration of symptoms
was longer in symptomatic patients (20.3months vs.
112.8months). However, there was no difference in pre-
operative EBD (symptom-free 11% vs. 10%). During the >
2-year follow-up, there was still no difference in age
(53.1 years vs. 54.8 years), and patients with satisfactory
symptom control underwent surgery later than those in
the symptomatic group (82.2months vs. 40.5months).
Table 1.














Achalasia (early stage) 48 46.2 Laparoscopic Heller-Dor Elective 2% (1/48) 0 7.3
Achalasia (advanced
stage, mega-esophagus)
2 43.3 Esophageal resection
with gastric, jejunal or
colonic replacement








2 60.5 Total esophagectomy
(Torek’s operation)
Emergency 50% (1/2) 0 15.5
Late reconstruction
after Torek operation
2 60.5 Reconstructive surgery
with gastric or colonic
replacement
Elective 0,0% 0 14.5
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DISCUSSION
The treatment strategy for patients with achalasia in cen-
ters specializing in esophageal diseases is determined in
close collaboration among gastroenterologists and sur-
geons. In addition to the ever growing variety of effective
medical interventions, patients with persistent symptoms
may undergo surgery at different stages and with different
timings. The first documented surgery for achalasia was
performed by Ernst Heller in 1913; it was an extramucosal
myotomy at the level of the cardia, thus reducing the pres-
sure of the LES and facilitating the passage of solid food
into the stomach.10 Originally, Heller recommended a
double (anterior and posterior) myotomy; however, a
simple myotomy, a procedure still used today, was
described by Zaaijer, a Dutch surgeon, in 1923.11 The tra-
ditional open surgeries of the esophagus (via thoracotomy
or laparotomy) have considerable morbidity rates. To
reduce them, the minimally invasive surgical technique is
currently an excellent alternative in the surgical treatment
of the functional disorders of the esophagus, including
esophageal achalasia. Our team has published several
papers on its favorable results in the minimally invasive
surgical treatment of benign esophageal disorders.7,12–16
Nowadays, the laparoscopic trans-hiatal technique is one
of the most accepted minimally invasive procedures in
the surgical treatment of esophageal achalasia. The proce-
dure is associated with low morbidity and ensures a long-
term symptom-free condition in a considerable number of
cases.17 In addition to the well-known benefits of laparo-
scopy (reduced postoperative pain, shorter hospital stay,
and better cosmetic results), a further favorable factor is
that the lower third and the abdominal segment of the
esophagus can be well explored through the hiatus and
that, technically, a myotomy and antireflux surgery can be
performed with precision.
Beyond an accurate diagnosis, medical treatment for
achalasia is determined by the physical capacity of the
patient and their response to the therapies. Smooth mus-
cle relaxants and botulinum toxin injected into the lower
esophageal sphincter may reduce dysphagia; however,
their effect is only temporary, and they may make a later
Heller myotomy more difficult.18–20 The efficacy of EBD is
between 70% and 80%,21 and newer comprehensive stud-
ies have confirmed a perforation rate of less than 1%,
which equals the rate of perforations not noticed during
Heller surgery.22 Although the rate of a favorable clinical
response to a surgical myotomy is better than that after
EBD, serial EBD may be an appropriate alternative to sur-
gical treatment.23 In a prospective, randomized study con-
ducted by Moonen et al., nearly the same success in
dysphagia control was demonstrated after five years;
however, this was only achieved after multiple dilations
in one-quarter of the EBD group.24 Persson et al. demon-
strated a significantly higher five-year symptom-free rate
after LHM than after EBD (95% and 65%, respectively),25
and the same trend was confirmed by three different
meta-analyses.17,26,27 When assessing the effect of different
clinical parameters on therapy, it was also shown that
patients below the age of 45 years benefited more from
the surgical treatment than from EBD.28
POEM, which requires a serious learning process and a
special surgical environment, is also not a clear alternative
to minimally invasive surgical treatment.29,30 One of the
main concerns with POEM is the high rate of gastroesoph-
ageal reflux, which develops after treatment. It appears,
however, that this method is useful with type III achalasia,
Table 2.
Follow-up Data after Laparoscopic Heller-Dor Procedure
Follow-up Interval First Follow-up 6–12 Months 12–24 Months > 24 Months
Proportion of patients with complaint 1/48 (2%) 8/48 (16.6%) 10/48 (20.8%) 9/48 (18.7%)
Type I 1/30 (3.3%) 5/30 (16.6%) 4/30 (13.3%) 4/30 (13.3%)
Type II 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%)
Type III 0/9 (0%) 3/9 (33.3%) 3/9 (33.3%) 2/9 (22%)
Diffuse esophageal spasm 0/5 (0%) 0/5 (0%) 3/5 (60%) 3/5 (60%)
Jackhammer 0/1 (0%) 0/1 (0%) 0/1 (0%) 0/1 (0%)
Postoperative reflux 0/48 (0%) 0/48 (0%) 3/48 (6.2%) 3/48 (6.2%)
Postoperative dysphagia 1/48 (2%) 8/48 (16.6%) 8/48 (16.6%) 7/48 (14.5%)
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Table 3.
























Ancona33 1995 RC LHMD 17 6 0% 4 94.2% 0% 5.8%
OHMD 17 6 0% 10 94.2% 5.8% 0.0%
Richards39 2004 RCT LHMD 22 6 0% 1 NA by pH: 9.1% 0.0%
LHM 21 6 0% 1 NA by pH: 47.6%
Boeckxstaens23 2011 RCT LHMD 106 24 12% NA 90% by pH: 23%,
by EGD: 21%
6.6%
EBD 95 24 4% NA 86% by pH: 15%,
by EGD: 19%
Moonen24 2016 RCT LHMD 105 60 11% NA 84% by pH: 34%
by EGD: 18%
NA
EBD 96 60 5% NA 82% by pH: 12%
by EGD: 14%




POEM 140 24 5% 2 99.3% by pH: 38.4%,
by EGD:
37.4%
Werner30 2019 RCT LHMD 109 24 7.3% NA 81.7% by pH: 30%,
by EGD: 29%
NA
POEM 112 24 2.7% NA 83% by pH: 30%,
by EGD: 44%




Rawlings42 2012 RCT LHMD 36 12 5.6% NA 90.9% by pH:41.7% 8.3%
LHMT 24 12 8.3% NA 93.1% by pH: 21.1% 4.1%
Torres-
Villalobos41
2018 RCT LHMD 38 24 2.6% 2.5 100% by pH: 10.5% NA
LHMT 35 24 0% 2.5 90% by pH: 31.5% NA
Kumaga40 2014 RCT LHMD 19 12 0% 2 90.9% by pH: 18% 18.0%
LHMT 22 12 4.5% 2 85.7% by pH: 38% 14.0%








RCT, randomized controlled trial; RC, retrospective cohort; CCS, case control study; OHMD, open Heller Myotomy with Dor semifundoplica-
tion; LHMD, laparoscopic Heller myotomy with Dor semifundoplication; LHMT, laparoscopic Heller myotomy with Toupet semifundoplication;
LHMN, laparoscopic heller myotomy with Nissen fundoplication; EBD, endoscopic balloon dilation; POEM, per-oral endoscopic myotomy;
LOS, length of stay; GERD, gastro-esophageal reflux disease; EGD, esophago-gastro-duodenoscopy; NA, not available.
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where it can ensure a longer myotomy than standard
LHM; at the same time, the efficacy of LHM is almost 85%
here as well.31 Another possible future indication for this
procedure is recurrent and unsuccessful cases.32
LAPAROSCOPIC HELLER–DOR SURGERY
Laparoscopic Heller–Dor surgery was introduced at the end
of the last century and since then has become the gold
standard in the surgical treatment of esophageal achalasia.33
It has excellent mortality and morbidity rates of 0.01%
and 6%, respectively,17 (Table 3) and it provides a long-
term symptom control rate of about 90%, the success of
which also depends on the Chicago Classification.31
(Table 3) Mucosal injury may occur during the proce-
dure in 6.9% (0–33%) of cases, and it may remain hidden
in most cases or may be treated immediately during sur-
gery.17 (Table 3)
Based on our own results, it can be established that the
success rate beyond 24months is 85.5%, which can be
considered 93.7% with the supplementary conservative
medical treatment of symptomatic patients. In the patient
group studied, one patient in total (1/48, 2%) developed a
surgery-related complication, esophageal mucosal lesion,
which was discovered with the swallowing X-ray per-
formed with a water-soluble contrast agent on postopera-
tive day 1. The injury was supposedly caused by
intraoperative thermal damage, which was not seen dur-
ing the endoscopic follow-up examination after the pri-
mary surgery. No complications were observed in the
other 47 patients (98%) in the group, and there was no
mortality. All in all, the clinical results of this study are
clearly consistent with international standards, consider-
ing both long-term symptomatic control and the morbidity
rate.
As to LHM, there are two issues to be discussed: achieving
a symptom-free status post-surgery (eliminating dyspha-
gia) and the course of postoperative reflux. Both factors
can basically be traced back to the proper performance of
the myotomy. The 2018 International Society of Diseases
of the Esophagus guidelines on achalasia state that a lapa-
roscopic Heller myotomy is recommended over a length
of at least 6 cm on the esophagus and 2 to 3 cm on the
stomach for effective control of symptoms.34 Two publica-
tions reported a myotomy that extended 3 cm onto the
stomach, which reduced the risk of delayed dyspha-
gia.35,36 Proximally, a myotomy of 6 to 8 cm in length is
recommended in general, but no comparative publica-
tions are available on the length of esophageal
myotomies.37 There is also a physiological basis to the
proper cutting of the fibers – the high-pressure zone of
the cardia is generally slightly shorter than 4 cm and
extends 2 cm from the Z-line in the oral direction.
Based on our previous clinical study, it is clear that an
inadequate myotomy, either in the aboral or the oral
direction, may cause recurrent symptoms, which can be
corrected with repeat surgery.38 Our current study also
demonstrates that recurrent symptoms are more common
in patients with a spastic-type esophageal disorder (TIII
achalasia and DES) than in those with TI or TII disease.
Our results are expressive primarily after 12 months,
although symptoms returned earlier among TIII cases (3/
9, 33%). The trend continues in the 1 to 2-year follow-up
period, since the rate of symptomatic patients is relatively
high in the spastic group (TIII: 33%; DES: 60%), while in
the case of the classic form, it does not change much
when analyzing the time intervals (6–12months: 14.5%;
12–24months: 20.8%; > 24months: 18.7%). We may thus
conclude that, in certain cases, the increased tone of the
esophagus may extend well above the level of the LES,
where conventional and a properly performed myotomy
cannot always reach.
The other myotomy-related complaint is the development
of GERD. Based on observations by Campos and other
authors, reflux occurs in 41.5% without an antireflux pro-
cedure and only in 14.5% with one, thus confirming that if
the LES, the main barrier, is damaged, reflux may be
expected.17,39 By completing the procedure with partial
fundoplication, the occurrence of postoperative reflux
can be decreased considerably, without increasing the
pressure of the LES. Both anterior (Dor, 180°) and poste-
rior (Toupet, 270°) semifundoplication are used widely af-
ter a cardiomyotomy. There is an argument between the
supporters of Dor and Toupet which fundoplication is
better. Those experts who are for Dor say that anterior
fundoplication is easier to perform the non-dissection of
the posterior part of the esophagus may help against
GERD. However, the supporters of Toupet state it may
keep the edges of the myotomy separated, reducing the
probability of recurrent dysphagia and reducing develop-
ment of GERD. Comparing these two methods there were
no significant differences between the three randomized
control trials and their meta-analysis regarding the postop-
erative dysphagia and GERD.40–44 (Table 3) Their use is
determined by the preference of the surgical team. In a
recent, large prospective clinical trial, laparoscopic Heller-
Dor procedure has proved to be successful regarding ac-
ceptable low morbidity (4.7%) and durable symptom con-
trol (89.5%) on long-term in 1001 achalasia patients.45
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Based on our results, it is clear that the rate of GERD after
a Heller–Dor procedure was minimal (6.2%, 3/48) in the
medium term (24-month follow-up), and was controlled
with conservative therapy.
PERSISTENT SYMPTOMS
Following surgical treatment of achalasia, there may be
various mechanisms for persistent or recurrent cases, and
the often unavoidable reoperations may require other sur-
gery types (remyotomy, esophageal resection and total
esophagectomy), on which our team has previously
reported.37 Nowadays, owing to precise diagnostic meth-
ods, misdiagnoses are rare, and inadequate surgery types
that decrease patients’ quality of life have also disap-
peared from the surgeon’s repertoire. The proper per-
formance of a myotomy is of great importance because a
cardiomyotomy that is insufficient in length or depth may
be the source of recurrent symptoms and, in certain cases,
a secondary epiphrenal diverticulum may call attention to
unsuccessful previous treatment. A myotomy without fun-
doplication is of historical importance, and the severe
GERD and resultant esophageal stricture that develop
later may require resection surgery.38
MEGAESOPHAGUS
The risk of esophageal cancer is increased by long-
lasting achalasia, marked esophageal dilation, and
mucus congestion.46,47
The best way to prevent cancer is timely treatment – pri-
marily surgical therapy. If a cardiomyotomy is performed
late, that is, after a sigmoid deformity of the esophagus
has developed, effective cancer prevention can no longer
be achieved; what is more, the results of radical surgery
are also unsatisfactory because of the late recognition.48,49
In the megaesophagus stage, the risk of aspiration pneu-
monia, malignant transformation, and malnutrition is
markedly high. Most patients have undergone innumera-
ble endoscopic and/or surgical procedures, and indica-
tions for surgery are continuously recurrent symptoms
and the sigmoid deformity of the esophagus. The morbid-
ity rate for radical intervention varies between 19% and
50%, with the most common complications being pneu-
monia and anastomotic leak. The mortality rate is
between 0 and 5.4%, the length of stay is 10 to 16 days,
and slightly more than one-quarter of patients will later
require endoscopic balloon dilation for anastomotic stric-
ture.50 All our patients scheduled for elective resection
had an afunctional, significantly dilated esophagus, and
their number (3/54, 5%) corresponded to the literature
data. Great care was taken to individualize the type of sur-
gery during surgical treatment, and this decision was
made by the surgical team with experience of esophageal
surgery after considering the patient’s physical condition,
the intraoperative characteristics and the long-term opti-
mal quality of life. In the case of reconstruction, all three
eligible organs were used (stomach, jejunum, and colon),
neither an anastomotic leak nor pneumonia was observed
after the interventions, and there was no mortality. The
swallowing function of these patients is now satisfactory,
and no anastomotic stricture or other complications were
found during the follow-up visits.
It was long maintained that the only surgical treatment
possible for megaesophagus is esophageal resection, and
stomach, jejunum, or colon was used as a replacement.51
Because of the surgical burden and the relatively high rate
of peri-operative morbidity, a cardiomyotomy, which may
result in symptomatic improvement, could become preva-
lent in high-risk cases. A number of authors have reported
a noticeable improvement in symptoms even in these
decompensated patients with sigmoid esophagus.52–55
Both postoperative functional assessments of the patients
and quality-of-life questionnaires confirm the justification
and usability of a myotomy. Mineo’s team performed a
Heller myotomy in 14 achalasia patients with sigmoid de-
formity of the esophagus. After 85months of follow-up,
the result was excellent or good in 72% of the cases, while
the postoperative dysphagia and regurgitation scores sig-
nificantly decreased and matched those observed in acha-
lasia patients operated on in the early stage.52 In patients
undergoing surgery for megaesophagus, numerous publi-
cations have confirmed the efficacy of LHM in achieving
postoperative symptom control, and resection was not
necessary in any of the patients as a result of a persistently
good quality of life.54,55
The fact that LHM is not always effective in the treatment of
sigmoid esophagus was demonstrated by Zaninotto et al. in
their analysis of more than 400 cases involving a myotomy
for esophageal achalasia. At the end of their long-term, pro-
spective study, they concluded that a high preoperative LES
pressure has a beneficial effect on the outcome of the sur-
gery, while a stage IV (sigmoid) esophagus has an adverse
effect. Radical esophagectomy is often unavoidable because
of the persistent symptoms, but, after informing the patient
properly, a minimally invasive myotomy is worth pursuing
as a first step in the hope of a positive response to therapy.31
In our own patient population, a young woman with sig-
moid esophagus underwent LHM after multiple unsuccessful
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endoscopic dilations, and satisfactory swallowing function
was observed for almost six months. However, since dys-
phagia returned after the complaint-free period, esophageal
resection with jejunal interposition (the Merendino proce-
dure) was performed. At present, after more than a decade
of follow-up, the patient is completely symptom-free, her
swallowing is unrestricted, and her quality of life is excellent.
POSTENDOSCOPIC ESOPHAGEAL INJURY
In large centers, a perforation rate of about 1%, as detailed
above, should be expected while the patient is treated with
EBD as nonsurgical treatment of achalasia. Performing the
intervention on a prepared patient and timely recognition of
the lesion by an experienced gastroenterologist are impor-
tant factors in the patient’s emergency surgery. The mortality
rate for esophageal perforation ranges between 18% and
22%–even despite early recognition and treatment. If the
time elapsed between injury and surgery exceeds 24hours,
the mortality rate may even reach 27 to 40%.56 In the case of
esophageal injury, a personalized treatment strategy is
required in each case, and the following factors should be
taken into account: etiology of the injury, existing underly-
ing esophageal disease, time from injury to diagnosis, septic
condition, comorbidities, and physical capacity.57 Post-EBD
esophageal perforations are traditionally treated surgically,
but therapeutic methods also include conservative treatment
and modern endoscopic techniques (over the scope clip
and stent implantation).58–61
Basically, early surgical treatment is required for larger
lesions that cannot be treated endoscopically in the case
of a contrast agent leak into the pleural and/or peritoneal
space. Many authors agree that a similar decision is war-
ranted with the involvement of a surgeon as soon as pos-
sible even for smaller lesions.62 Time elapsed since a
perforation has a considerable effect on the success of the
surgery, although there is experience with both early and
later (> 24 hours) successful laparoscopic primary clo-
sures in the literature.62,63 In our practice, primary suture
repair is used in cases that are recognized early, within
24 hours, and it is always completed with the cardiomyot-
omy and antireflux procedure, which has a beneficial
effect on the healing of the lesion and, at the same time,
may result in long-term symptom-free status.
In the case of perforations beyond 24hours, patients usually
undergo resection without reconstruction (on rare occasion,
with immediate reconstruction) because of the septic condi-
tion that has developed and the reduced tendency of the
esophageal wall to heal. In the case of megaesophagus, a
worse-than-average condition of the esophagus supports
resection which is worth including during surgical treatment
in all cases. In tertiary centers with experience of esopha-
geal resection, mortality rates similar to that of primary
suture repair can be achieved (17% [0–43%] vs. 12% [0–
31%]).64–65 The importance of a multidisciplinary approach
and a correctly chosen treatment strategy is highlighted by a
study conducted at our department, which summarized
cases of spontaneous esophageal perforation and demon-
strated an acceptably low mortality rate (6.6%) owing to
timely and well executed procedures.66
Every patient in our acute surgery group was admitted to
our unit for an esophagoscopy-associated injury. The two
early cases (recognized within 24 hours), primary suture
repair occurred with Heller–Dor surgery, taking the condi-
tion of the patients into account, while esophageal resec-
tion without reconstruction was performed in the two
other cases with an old perforation complicated by mega-
esophagus. There was no mortality or notable morbidity
in the emergency group.
CONCLUSION
Laparoscopic Heller–Dor surgery is a safe and effective
surgical method for treating esophageal achalasia.
Symptom control in patients who have undergone mini-
mally invasive surgery is adequate even in the long term,
and the rate of postoperative reflux is low. However,
patients with the spastic type may develop recurrent
symptoms at a higher rate. Advanced and emergency con-
ditions are still a major challenge for surgeons, and choos-
ing the proper therapeutic strategy depends on several
factors. On the whole, surgery for achalasia is only recom-
mended in institutions where every aspect of the condi-
tion can be managed effectively and reliably.
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